Chang Yeol Lee
Yonsei University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Chang Yeol Lee.
Advanced Materials | 2012
Cheng Guo Li; Kwang Lee; Chang Yeol Lee; Manita Dangol; Hyungil Jung
A minimally invasive blood-extraction system is fabricated by the integration of an elastic self-recovery actuator and an ultrahigh-aspect-ratio microneedle. The simple elastic self-recovery actuator converts finger force to elastic energy to provide power for blood extraction and transport without requiring an external source of power. This device has potential utility in the biomedical field within the framework of complete micro-electromechanical systems.
Biomedical Microdevices | 2013
Chang Yeol Lee; Yong Sung You; Sung Ho Lee; Hyungil Jung
Intravitreal injection is widely used for easy control of drug levels in posterior segment of the eye by injecting the drug directly with hypodermic needles. Patients, however, often experience complications from intravitreal injection due to repeated injections, increased intraocular pressure, and infection. In addition, injected drug reflux after intravitreal injection makes it challenging to maintain predetermined drug dose due to the drug loss through backward effusions. Here, we described that the Tower Microneedle can reduce initial reflux and bleb formation due to its smaller outer diameter compared to a traditional hypodermic needle. Furthermore, we use phenylephrine hydrochloride for pupil expansion and demonstrated that Tower Microneedle induced similar pupil expansions using only half the drug volume, in the same period of time, compared to the 31 Gauge hypodermic needle. Consequently, Tower Microneedle achieves the same therapeutic effect in the vitreous body using fewer drugs than a traditional hypodermic needle due to the decreased backward drug effusion. Tower Microneedle described herein holds great promise for intravitreal injection with less reflux and lower drug dosage.
PLOS ONE | 2014
Yong Sung You; Chang Yeol Lee; Chengguo Li; Sung Ho Lee; Kibom Kim; Hyungil Jung
Several critical ocular diseases that can lead to blindness are due to retinal disorders. Subretinal drug delivery has been developed recently for the treatment of retinal disorders such as hemorrhage because of the specific ocular structure, namely, the blood retinal barrier (BRB). In the present study, we developed an Arched Micro-injector (ARCMI) for subretinal drug delivery with minimal retinal tissue damage. ARCMIs were fabricated using three major techniques: reverse drawing lithography, controlled air flow, and electroplating. In order to achieve minimal retinal tissue damage, ARCMIs were fabricated with specific features such as a 0.15 mm−1 curvature, 45° tip bevel, 5 mm length, inner diameter of 40 µm, and an outer diameter of 100 µm. These specific features were optimized via in-vitro experiments in artificial ocular hemispherical structures and subretinal injection of indocyanine green in porcine eye ex-vivo. We confirmed that the ARCMI was capable of delivering ocular drugs by subretinal injection without unusual subretinal tissue damage, including hemorrhage.
Biochip Journal | 2015
Chang Yeol Lee; Yonghao Ma; Yong Sung You; Hyoung Eun Kim; Young Dook Byeon; Hyungil Jung
Tower Microneedle was developed with minimal ocular tissue damages even reflux, while no study was reported with intravitreal injection of ophthalmic drug via Tower Microneedle into the eye. Intravitreal injection of anti-vascular endothelial growth factor antibodies via the Tower Microneedle or a 30-G hypodermic needle was performed 1 week after argon laser irradiation into the retina of the mouse models. Less bleb formation was occurred with Tower Microneedle than 30-G hypodermic needle, while both needles led to comparable degrees of anti-angiogenesis in the retina after intravitreal injection of anti-vascular endothelial growth factor antibodies over 100 ng/μL concentration. Conclusively, the Tower Microneedle can deliver anti-vascular endothelial growth factor antibody into the posterior segment of the eye with minimal bleb formation after intravitreal injection.
Biomedical Microdevices | 2013
Cheng Guo Li; Chang Yeol Lee; Kwang Lee; Hyungil Jung
Lab on a Chip | 2015
Cheng Guo Li; Manita Dangol; Chang Yeol Lee; Mingyu Jang; Hyungil Jung
Advanced Healthcare Materials | 2013
Chang Yeol Lee; Kwang Lee; Yong Sung You; Sung Ho Lee; Hyungil Jung
Biomedical Microdevices | 2016
Yonghao Ma; Chang Yeol Lee; Cheng Guo Li; Yong Sung You; Ho Lee Sung; Hyungil Jung
18th International Conference on Miniaturized Systems for Chemistry and Life Sciences, MicroTAS 2014 | 2014
Dae Sik Lee; Chang Yeol Lee; Hyungil Jung; Mun Yeon Jung
한국실험동물학회 학술발표대회 논문집 | 2013
Chang Yeol Lee; S.I. Kim; Sung Kyu Kim; So-Young Kim; Hyungil Jung